Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has received positive feedback on its patent application for a new AI-based method to identify cancer vaccine targets, which could enhance its portfolio of personalized cancer vaccines. The method focuses on Endogenous Retroviruses (ERVs) as targets, a novel approach that may benefit a wider range of cancer patients. This development potentially solidifies the company’s innovative stance in the personalized cancer vaccine market.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
